Stewart Levine, MD
Ophthalmology · Bayside, NYNPI 1760408678
Payments from drug & device makers
Across 264 payments — averaging $30.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$751
- Sun Pharmaceutical Industries Inc.$746
- Bausch & Lomb Americas Inc.$555
- Alcon$490
- Aerie Pharmaceuticals, Inc.$442
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,81196%
- Education$180%
- Gifts$370%
- Entertainment$2603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,877 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $751 |
| Sun Pharmaceutical Industries Inc. | 24 | $746 |
| Bausch & Lomb Americas Inc. | 24 | $555 |
| Alcon | 19 | $490 |
| Aerie Pharmaceuticals, Inc. | 7 | $442 |
| Merz North America, Inc. | 4 | $349 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $294 |
| Optos, Inc. | 3 | $260 |
| Harrow Eye, LLC | 9 | $228 |
| Novartis | 5 | $210 |
| Maculogix, Inc. | 1 | $209 |
| NEW World Medical,inc. | 5 | $207 |
| Carl Zeiss Meditec USA, Inc. | 2 | $190 |
| Amgen(2 entities) | 9 | $176 |
| Glaukos Corporation | 5 | $174 |
| Ocular Therapeutix, Inc. | 8 | $160 |
| Astellas Pharma US Inc | 5 | $159 |
| Topcon Healthcare, Inc. | 3 | $101 |
| Thea Pharma Inc. | 4 | $75 |
| Shire North American Group Inc | 3 | $69 |
| Iridex Corporation | 2 | $67 |
| Stryker | 1 | $50 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Carl Zeiss Meditec, Inc. | 2 | $38 |
| Galderma Laboratories, L.p. | 2 | $37 |
| Omeros Corporation | 2 | $35 |
| Ivantis, Inc | 1 | $31 |
| Rxsight Inc | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Quidel Corporation | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| LKC Technologies, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$354
- XEOMIN$269
- P200DTx$242
- P200T$242
- P200TE$242
- P200TxE$242
- CEQUA$241
- Rhopressa$238
- Rocklatan$238
- AdaptDx$209
- VYZULTA$200
- ENVISTA$150
- CIRRUS HD-OCT$138
- Ahmed Glaucoma Valve$136
- Kahook Dual Blade$136
- XIIDRA$118
- ASCLERA$102
- LOTEMAX SM$100
How this compares
$8,125 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 65 | $42,003 |
| RestasisCyclosporine | 15 | $20,226 |
| Alphagan PBrimonidine Tartrate | 37 | $18,427 |
| VyzultaLatanoprostene Bunod | 30 | $17,992 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $14,100 |
| Brimonidine Tartrate | 145 | $7,546 |
| LumiganBimatoprost | 12 | $6,837 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 308 | $6,460 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $4,571 |
| Latanoprost | 349 | $3,507 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 15 | $2,659 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 45 | $1,936 |
| Ketorolac Tromethamine | 50 | $1,924 |
| Prednisolone Acetate | 50 | $1,542 |
| Dorzolamide Hcl | 69 | $1,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $442 | $56,10391 claims |
| AbbVieRestasis, Alphagan P, Lumigan | $1,877 | $45,49164 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $555 | $17,99230 claims |
| AlconSimbrinza | $490 | $4,57118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Bayside
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.